As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
We are living in a time of extraordinary cognitive convenience and that isn’t always a good thing. AI isn’t the real risk to leadership — shallow thinking is.
We are living in a time of extraordinary cognitive convenience and that isn’t always a good thing. AI isn’t the real risk to leadership — shallow thinking is.